Clinical Trial Update: Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing the safety and preliminary activity of pemetrexed (ALIMTA) for recurrent central nervous system lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Central Nervous System Lymphoma | Phase 1 | Status: COMPLETED